Peer-reviewed articles in 2019

  • Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessyet J al. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial JAMA Surg. 2020;doi:10.1001/jamasurg.2019.5410 (2019 online ahead of print).
  • Papakonstantinou A, Matikas A, Bengtsson NO, Malmström P, Hedayati E et al. Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial. Cancer. 2019;doi:10.1002/cncr.32653.
  • Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet. 2019;doi:10.1016/S0140-6736(19)32955-1.
  • Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, et al. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res. 2019;21:142.
  • Witzel I, Loibl S, Wirtz R, Fasching PA, Denkert C, et al. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer. 2019 2019;121:1009–1015.
  • Heitz F, Kümmel S, Lederer B, Solbach C, Engels K, Ataseven B, Sinn B, Blohmer JU, Denkert C, Barinoff J, Fisseler-Eckhoff A, Loibl S. Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Geburtshilfe Frauenheilkd. 2019;79:1110-1117.
  • Hui R, Pearson A, Cortés J, Campbell C, Poirot C, et al. Lucitanib for the treatment of HR(+)/ HER2(-) metastatic breast cancer: results from the multicohort phase II FINESSE study. Clin Cancer Res. 2019;doi:10.1158/1078-0432.CCR-19-1164.
  • Golshan M, Wong SM, Loibl S, Huober JB, O'Shaughnessy J, et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. Eur J Surg Oncol. 2019;doi:10.1016/j.ejso.2019.10.002
  • Papakonstantinou A, Hedayati E, Hellström M, Johansson H, Gnant M, et al. Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. Acta Oncol. 2020;59:75–81 (2019 online ahead of print).
  • Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, et al. Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial. Cancers (Basel). 2019;11:1186.
  • Krug D, Lederer B, Seither F, Nekljudova V, Ataseven B, et al. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Ann Surg Oncol. 2019;26:3892-3901.
  • Kümmel A, Kümmel S, Blohmer JU, Faridi A, Nitz U, et al. Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPRÄC. Breast Care (Basel). 2019;14:165-169.
  • Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, et al. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019;117:91-98.
  • Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, et al. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer. 2019;26:826-834.
  • Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;doi: 10.1093/annonc/mdz158.
  • Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, et al. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol. 2019;37:2226-2234.
  • Laakmann E, Witzel I, Fasching PA, Rezai M, Schem C, et al. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res. 2019;21:60.
  • Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, et al. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. Eur J Cancer. 2019;114:76-88.
  • Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, et al. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Res Treat. 2019;176:557-568.
  • Kuemmel S, Holtschmidt J, Gerber B, Von der Assen A, Heil J, et al. Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. J Clin Oncol. 2019;37:1490-1498.
  • Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, et al. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clin Cancer Res. 2019;25:3986-3995.
  • Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, et al. Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients. Reprod Biomed Online. 2019; 38:835-844.
  • Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, et al. Genome-wide association study of germline variants and breast cancer-specific mortality. Br J Cancer. 2019;120:647-657.
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:1440-1452.
  • Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, et al. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. Int J Cancer. 2019;145:857-868.
  • Eggemann H, Bernreiter AL, Reinisch M, Loibl S, Taran FA et al. Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. Br J Cancer. 2019;120:301-305.
  • Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019;104:21-34.
  • Shu X, Wu L, Khankari NK, Shu X-O, Wang TJ et al. (Breast Cancer Association Consortium). Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. Int J Epidemiol. 2019;48:795–806.
  • Froehlich K, Schmidt A, Heger JI, Al-Kawlani B, Aberl CA, Jeschke U, Loibl S, Markert UR. Breast cancer, placenta and pregnancy. Eur J Cancer. 2019;115:68-78. Review.


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd